Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback